Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi

F. Zaja, S. Ferrero, C. Stelitano, A. Ferrari, F. Salvi, A. Arcari, G. Musuraca, B. Botto, M. Spina, C. Cellini, C. Patti, A.M. Liberati, C. Minotto, S.A. Pileri, M. Ceccarelli, S. Volpetti, A. Ferranti, D. Drandi, E. Montechiarello, M. LadettoJ. Carmichael, R. Fanin

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)e203-e206
Number of pages4
JournalHaematologica
Volume102
Issue number5
DOIs
Publication statusPublished - 2017

Keywords

  • bendamustine
  • cereblon
  • cytarabine
  • ibrutinib
  • immunoglobulin heavy chain
  • Ki 67 antigen
  • lenalidomide
  • peptides and proteins
  • protein bcl 2
  • rituximab
  • unclassified drug
  • adult
  • aged
  • anemia
  • autologous stem cell transplantation
  • clinical article
  • febrile neutropenia
  • female
  • follow up
  • gene rearrangement
  • human
  • International Prognostic Index
  • Letter
  • male
  • mantle cell lymphoma
  • minimal residual disease
  • multicenter study
  • multiple cycle treatment
  • nephrotoxicity
  • nonhodgkin lymphoma
  • overall survival
  • phase 2 clinical trial
  • polymerase chain reaction
  • progression free survival
  • prospective study
  • protein expression
  • thrombocytopenia

Cite this

Zaja, F., Ferrero, S., Stelitano, C., Ferrari, A., Salvi, F., Arcari, A., Musuraca, G., Botto, B., Spina, M., Cellini, C., Patti, C., Liberati, A. M., Minotto, C., Pileri, S. A., Ceccarelli, M., Volpetti, S., Ferranti, A., Drandi, D., Montechiarello, E., ... Fanin, R. (2017). Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi. Haematologica, 102(5), e203-e206. https://doi.org/10.3324/haematol.2016.154211